- Home
- VSTM vs ELTX Comparison
VSTM vs ELTX Comparison
Compare VSTM & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- ELTX
- Stock Information
- Founded
- VSTM 2010
- ELTX 2011
- Country
- VSTM United States
- ELTX United States
- Employees
- VSTM N/A
- ELTX N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- ELTX Health Care
- Exchange
- VSTM Nasdaq
- ELTX Nasdaq
- Market Cap
- VSTM 132.0M
- ELTX 49.7M
- IPO Year
- VSTM 2012
- ELTX 2021
- Fundamental
- Price
- VSTM $3.88
- ELTX $4.16
- Analyst Decision
- VSTM Strong Buy
- ELTX Buy
- Analyst Count
- VSTM 8
- ELTX 2
- Target Price
- VSTM $14.57
- ELTX $10.00
- AVG Volume (30 Days)
- VSTM 1.1M
- ELTX 16.1K
- Earning Date
- VSTM 11-06-2024
- ELTX 11-07-2024
- Dividend Yield
- VSTM N/A
- ELTX N/A
- EPS Growth
- VSTM N/A
- ELTX N/A
- EPS
- VSTM N/A
- ELTX N/A
- Revenue
- VSTM $10,000,000.00
- ELTX N/A
- Revenue This Year
- VSTM N/A
- ELTX N/A
- Revenue Next Year
- VSTM $125.69
- ELTX N/A
- P/E Ratio
- VSTM N/A
- ELTX N/A
- Revenue Growth
- VSTM N/A
- ELTX N/A
- 52 Week Low
- VSTM $2.10
- ELTX $2.96
- 52 Week High
- VSTM $14.22
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- VSTM 63.77
- ELTX 40.82
- Support Level
- VSTM $3.11
- ELTX $4.05
- Resistance Level
- VSTM $3.76
- ELTX $4.89
- Average True Range (ATR)
- VSTM 0.33
- ELTX 0.28
- MACD
- VSTM 0.04
- ELTX -0.06
- Stochastic Oscillator
- VSTM 94.26
- ELTX 27.37
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.